A real-world retrospective analysis of the management of metastatic castrate-resistant prostate cancer in Ontario, Canada from 2010 - 2018.


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
03 2023
Historique:
received: 06 07 2022
revised: 28 10 2022
accepted: 27 11 2022
pubmed: 15 1 2023
medline: 8 3 2023
entrez: 14 1 2023
Statut: ppublish

Résumé

We sought to quantify mCRPC patient treatment patterns and survival across multiple lines of therapy after prior androgen-receptor-axis-targeted therapy (ARAT) failure. Individuals diagnosed with prostate cancer between 2010 and 2018 were identified in the Ontario Cancer Registry (OCR). An algorithm was created to identify patients with mCRPC that was aligned to Prostate Cancer Clinical Trials Working Group 3 criteria (PCWG3) and validated with Canadian clinical experts. In the mCRPC setting, treatment patterns were assessed by line of therapy, and survival was calculated from treatment initiation until death or lost to follow-up. 64,484 men were diagnosed withprostate cancer in Ontario between 2010 and 2018with 5,588 men assessed to have mCRPC and 2,970 (53%) of those received first-line systemic treatment. Across the first-, second- and third-line of therapy, ARATs (abiraterone and enzalutamide) were the most used therapies. Survival for mCRPC patients treated with ARATs in first-, second- and third-line were 13.0 (95% CI, 11.6 - 14.5), 11.5 (95% CI, 10.1 - 13.4) and 8.9 (95% CI, 7.4 - 10.2) months, respectively. Survival for mCRPC patients treated with taxanes in first, second- and third-line were 16.7 (95% CI, 14.8 - 18.0), 11.3 (95% CI, 10.1 - 12.5) and 7.8 (95% CI, 6.5 - 10.6) months, respectively. No statistical difference in overall survival was found between taxanes and ARATs. In this analysis of a large retrospective cohort of Canadian men with mCRPC, we found that survival in patients treated with ARATs and taxanes was fairly similar across all lines of therapy. Importantly, this trend was maintained in ARAT-exposed patients, where sequential ARAT and taxanes offered similar survival. These data may help inform optimal sequencing of therapies in mCRPC.

Identifiants

pubmed: 36641303
pii: S1078-1439(22)00482-3
doi: 10.1016/j.urolonc.2022.11.019
pii:
doi:

Substances chimiques

Taxoids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

146.e13-146.e22

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Daniel M Moldaver and Derek L Clouthier are AstraZeneca employees. Daniel M Moldaver and Derek L Clouthier have AstraZeneca stocks from 2020 to present and 2019 to present, respectively.

Auteurs

Daniel M Moldaver (DM)

AstraZeneca Canada, Mississauga, ON.

Shazia Hassan (S)

HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON.

Soo Jin Seung (SJ)

HOPE Research Centre, Sunnybrook Research Institute, Toronto, ON.

Jonathan Edwin (J)

AstraZeneca Canada, Mississauga, ON.

Derek L Clouthier (DL)

AstraZeneca Canada, Mississauga, ON.

Francisco E Vera-Badillo (FE)

Department of Oncology, Queen's University, Kingston, ON. Electronic address: Francisco.VeraBadillo@kingstonhsc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH